Industry News

CRISPR Therapeutics to expand into autoimmune disease

Dec. 5, 2023
The announcement comes days before the FDA's regulatory decision on the CRISPR-based gene-therapy exa-cel.

Sanofi AI push continues with Aqemia collab

Dec. 5, 2023
Sanofi has signed a multi-year $140 million research deal with the Paris-based startup

AstraZeneca partners with Absci on AI-driven oncology asset

Dec. 4, 2023
The collab will give AstraZeneca access to Absci's generative AI platform with the goal of accelerating the discovery of a potential new cancer treatment

Roche acquires Carmot Therapeutics in $2.7B deal

Dec. 4, 2023
The merger positions Roche with both injectable and oral obesity drug candidates.

Astellas, Phenomic enter solid tumor cell therapy partnership

Dec. 1, 2023
News of the partnership broke a day after its announcement of a $500 million deal with Boehringer Ingelheim

Amgen, Amazon Web Services expand AI collaboration

Dec. 1, 2023
The biotech plans to harness AWS's global infrastructure and services for its new assembly and packaging site in Ohio

Lilly, PRISM BioLab ink PPI discovery deal

Nov. 30, 2023
Protein-protein interactions were also a key piece of Lilly’s $2.4 billion Dice buyout this year

AbbVie to buy ImmunoGen in a $10.1B ADC-driven deal

Nov. 30, 2023
In one of the largest biopharma M&A deals this year, AbbVie grabs the only approved ovarian cancer ADC

Boehringer teams with Phenomic AI to discover stroma-rich cancer targets

Nov. 29, 2023
In a deal that could exceed $500 million, Boehringer will use Phenomic's scTx single-cell transcriptomics platform to develop first-in-class medicines

Emergent receives $75M from BARDA for anthrax vax supply

Nov. 29, 2023
BARDA has awarded a contract option to Emergent for the acquisition of its newly licensed anthrax vaccine

Avidity, BMS ink $2.3B cardio deal

Nov. 28, 2023
The expanded partnership will focus on antibody oligonucleotide conjugates

Boehringer to use IBM AI model in drug discovery pact

Nov. 28, 2023
The drugmaker will use a pre-trained AI model to make the vision of in silico biologic drug discovery a reality.

FDA delays decision on BMS-2seventy cancer therapy

Nov. 27, 2023
An FDA AdComm will meet to discuss the companies’ proposed use of Abecma in earlier lines of treatment for multiple myeloma

Novartis recalls Sandimmune oral solution due to crystallization concerns

Nov. 27, 2023
The drugmaker has not received any reports of adverse events related to this issue

InDex halts phase 3 ulcerative colitis trial

Nov. 22, 2023
The Swedish biotech has discontinued a trial of its lead asset following the advice of an independent data monitoring committee

Evelo Biosciences announces dissolution

Nov. 22, 2023
After exhaustive efforts to explore funding alternatives, the biotech will be closing its doors

Genentech, Nvidia ink drug discovery AI partnership

Nov. 21, 2023
Aiming to fast-track drug discovery, the two will link experimental data to algorithms with AI precision.

BeiGene stakes up to $1.33B on Ensem CDK2 inhibitor

Nov. 21, 2023
The partners will work to bring the potential first-in-class CDK2-specific drug to the clinic

Oxurion faces bankruptcy as diabetic retinopathy trial falls short

Nov. 20, 2023
The company’s financial woes deepen as its trial for diabetic macular edema yields disappointing results.

Bayer recalls one lot of cancer drug

Nov. 20, 2023
The drugmaker is recalling one lot of Vitrakvi following the discovery of microbial contamination

With a focus on prostate cancer, Astellas buys Propella Therapeutics

Nov. 17, 2023
In the deal, Astellas will pick up a phase 1 injectable version of J&J's Zytiga

Lilly to invest $2.5M in German injectable facility

Nov. 17, 2023
The site will support the surging demand for the drugmaker's diabetes and obesity portfolio

FDA approves BMS lung cancer drug

Nov. 16, 2023
The tyrosine kinase inhibitor was the driving force behind BMS' $4.1 billion acquisition of Turning Point Therapeutics

Vertex, CRISPR nab world’s first approval for CRISPR-edited therapy

Nov. 16, 2023
The UK has approved exa-cel for the treatment of sickle cell disease and transfusion-dependent beta thalassemia

Kite to expand cancer collab with Arcellx

Nov. 15, 2023
The Gilead company is extending its partnership into lymphomas and multiple myeloma

Atreca cuts workforce by 40%, again

Nov. 15, 2023
The California-based immunotherapy biotech has announced its third reorg in recent history

With an eye on bone cancer drug, Telix looks to buy QSAM

Nov. 14, 2023
The Australian biopharma has proposed a $33.1 million acquisition of the bone cancer specialist

AstraZeneca's push to expand Imfinzi in lung cancer fails in trial

Nov. 14, 2023
A phase 3 trial to evaluate concurrent Imfinzi administration with chemoradiotherapy failed to meet its endpoint

Sandoz opens new antibiotic plant and new biosimilar development center

Nov. 13, 2023
The drugmaker has inaugurated a penicillin production facility in Kundl, Austria and a new biosimilar development center in Holzkirchen, Germany

Pfizer sells lead antifungal asset from Amplyx buy

Nov. 13, 2023
Switzerland-based Basilea Pharmaceutica will acquire the rights to fosmanogepix, a phase 3-ready broad-spectrum antifungal candidate